Recent investigations have converged on the intersection of GLP-1|GIP|glucagon receptor agonist therapies and dopamine signaling. While GCGR activators are commonly employed for managing type 2 diabetes, their unexpected consequences on reward circuits, specifically influenced by DA pathways, are